Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Macropa-NCS is conjugated to trastuzumab as well as to the prostate-specific membrane antigen-targeting compound RPS-070.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
25 mg | 約10-14 週間 | ¥ 486,500 |
50 mg | 約10-14 週間 | ¥ 638,000 |
100 mg | 約10-14 週間 | ¥ 849,500 |
In vitro | A stock solution of macropa-NCS at 4.4 mg/mL was prepared in a 0.1 M NaHCO3 buffer (pH 9.1) with 0.154 M NaCl and stored at -80 °C. To a saline solution of Tmab (74 μL), macropa-NCS (52 μL) and NaHCO3 buffer (266 μL) were added, resulting in final concentrations of 5.1 mg/mL for Tmab and 0.59 mg/mL for macropa-NCS. It was estimated that macropa-NCS was present at a 16-fold molar excess relative to Tmab, taking into account the molecular weight of macropa-NCS (tetra-TFA salt) as 1045.76 g/mol[1]. |
分子量 | 589.66 |
分子式 | C27H35N5O8S |
CAS No. | 2146095-31-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Macropa-NCS 2146095-31-8 Others Macropa NCS MacropaNCS Inhibitor inhibitor inhibit